NCT06821464View on ClinicalTrials.gov

A Trial of HRS-9813 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions
Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
Interventions
DRUG

HRS-9813

Initial dose to planned dose（low dose）

DRUG

HRS-9813

Initial dose to planned dose（high dose）

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY